Miami-based Bascom Palmer Eye Institute is the first facility in Florida to place a new implant to slow the symptoms of macular telangiectasia type 2.
Thomas Albini, MD, led the procedure to place the Encelto microscopic implant. The new technology, which uses gene therapy, is the first FDA-approved treatment designed specifically for MacTel treatment, according to a Feb. 19 news release from the University of Miami Miller School of Medicine.
MacTel affects about one in 10,000 individuals and damages the retina in both eyes.
The FDA has approved the treatment for use at any stage of the disease, the release said.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.